News from contractpharma.comFollowNews from contractpharma.comAll of today’s top news stories from contractpharma.com. Get the full analysis behind how media bias impacts breaking news.Ground News has come across 344 headlines reported on by contractpharma.com during the past 3 months. contractpharma.com’s aggregated media bias check is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is contractpharma.com credible or reliable? Our Factuality score answers both of those questions. When it comes to contractpharma.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow All of today’s top news stories from contractpharma.com. Get the full analysis behind how media bias impacts breaking news. Ground News has come across 344 headlines reported on by contractpharma.com during the past 3 months. contractpharma.com’s aggregated media bias check is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is contractpharma.com credible or reliable? Our Factuality score answers both of those questions. When it comes to contractpharma.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about contractpharma.comWhere is contractpharma.com located?contractpharma.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top contractpharma.com NewsPfizer names Chris Boshoff as new R&D chief, WSJ reports75% Center coverage: 4 sources(Reuters) – Pfizer has named company veteran Chris Boshoff, who led the drugmaker’s cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday. (Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)See the StoryStock Markets · JapanKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - Kura Oncology (NASDAQ:KURA)67% Center coverage: 3 sources– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly…See the StoryHalozyme drops Evotec buyout bid; Patient dies in Neurogene trial100% Center coverage: 1 sourcesEvotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.See the StoryLatest News StoriesTopics Most Covered by contractpharma.comCancerVaccinesMerckAstraZenecaArtificial IntelligenceCancerVaccinesMerckSources Covering Similar Topicsstocktitan.netGEN - Genetic Engineering and Biotechnology News…pharmaceutical-technology.comcitybizpipelinereviewstocktitan.netGEN - Genetic Engineering and Biotechnology News…pharmaceutical-technology.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
